The University of Chicago Header Logo

Connection

Diarmuid Moran to Cell Line, Tumor

This is a "connection" page, showing publications Diarmuid Moran has written about Cell Line, Tumor.
Connection Strength

0.270
  1. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol Cancer Ther. 2014 Jun; 13(6):1611-24.
    View in: PubMed
    Score: 0.076
  2. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
    View in: PubMed
    Score: 0.058
  3. Microencapsulation of engineered cells to deliver sustained high circulating levels of interleukin-6 to study hepatocellular carcinoma progression. Cell Transplant. 2006; 15(8-9):785-98.
    View in: PubMed
    Score: 0.043
  4. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 2005 Apr; 25(2):445-57.
    View in: PubMed
    Score: 0.041
  5. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Mol Cancer Ther. 2016 07; 15(7):1746-56.
    View in: PubMed
    Score: 0.022
  6. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. PLoS One. 2013; 8(8):e72407.
    View in: PubMed
    Score: 0.018
  7. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.